Tuberculosis

Tuberculosis (TB) kills nearly 2 million people annually and has been declared a global health emergency by the World Health Organization (WHO). Drug resistance and patient noncompliance are two of the key factors that affect the success rate of conventional treatments, underlining the urgent need for novel anti-TB therapeutic targets and new drugs that could circumvent these problems. During the last decade, exoenzymes secreted into the host cell by Mycobacterium tuberculosis (Mtb) to attenuate host immune defenses have emerged as promising therapeutic targets. NP inhibitors of protein tyrosine phosphatase A (PtpA) and B (PtpB) have demonstrated significant therapeutic potential. In addition, the InhA enoyl reductase is a major Mtb drug target highly attractive for inhibition by NP, validated clinically by the prodrugs isoniazid and ethionamide. Finally, recent structural genomics approaches have led to the identification and characterization of putative anti-TB drug targets such as for example PknA and PknB Mtb kinases, for which bioactive NP may function as reliable tools for pharmacological validation as well as lead candidates for anti-TB drug discovery.

 

 To access your WG4 please log in

MEMBERS 

Gunter Schneider     (Group leader)
Jette Elisabeth Kristiansen
Gian Maria Fimia
Anna Hirsch
Hartcoorn Ruben 
Priscille Brodin